ABSTRACT: Tissue-engineered constructs (TECs) combining resorbable calcium-based scaffolds and mesenchymal stem cells (MSCs) have the capability to regenerate large bone defects. Inconsistent results have, however, been observed, with a lack of osteoinductivity as a possible cause of failure. This study aimed to evaluate the impact of the addition of low-dose bone morphogenetic protein-2 (BMP-2) to MSC-coral-TECs on the healing of clinically relevant segmental bone defects in sheep. Coral granules were either seeded with autologous MSCs (bone marrow-derived) or loaded with BMP-2. A 25-mm-long metatarsal bone defect was created and stabilized with a plate in 18 sheep. Defects were filled with one of the following TECs: (i) BMP (n ¼ 5); (ii) MSC (n ¼ 7); or (iii) MSC-BMP (n ¼ 6). Radiographic followup was performed until animal sacrifice at 4 months. Bone formation and scaffold resorption were assessed by micro-CT and histological analysis. Bone union with nearly complete scaffold resorption was observed in 1/5, 2/7, and 3/6 animals, when BMP-, MSC-, and MSC-BMP-TECs were implanted, respectively. ] for BMP-, MSC-, and MSC-BMP-TECs, respectively. Increased scaffold resorption rate using BMP-TECs was the only potential side effect observed. In conclusion, although the dual delivery of MSCs and BMP-2 onto a coral scaffold further increased bone formation and bone union when compared to single treatment, results were non-significant. Only 50% of the defects healed, demonstrating the need for further refinement of this strategy before clinical use. ß
In the United-States, the incidence of bone defect repair procedures is more than half a million per year (i.e., healthcare costs exceeding $2.5 billion annually) and the worldwide incidence is increasing and expected to double by 2020. 1, 2 Advances in surgical and medical techniques and patient care have improved the treatment of severe bone losses resulting from high-energy trauma, infection, developmental deformities, revision surgery, and tumor resection. Of all fractures treated, 0.4% are critical-sized segmental bone defects (CSD), in which the endogenous mechanisms, impaired by an adverse local environment, are insufficient to achieve repair. 3 These lesions are best treated with bone replacement therapies.
For defects less than 50 mm in length, autologous bone grafting is the standard of care. 3 However, this procedure is ineffective in larger defects, limited in supply, and constrained by significant donor site morbidity and costs. [3] [4] [5] As a result, alternative tissueengineering (TE) strategies that combine off-the-shelf resorbable calcium-based scaffolds with mesenchymal stem cells (MSCs) have been investigated. While many animal studies have established proof-of-concept for cell-based therapy in the field of bone TE, transfer from bench to bedside has been limited solely to case reports. 1, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Inconsistent results have indeed contrasted with the steady bone regeneration observed with autologous bone grafts implanted under similar experimental conditions, limiting large-scale clinical application. Among the causes responsible for failure to bone regeneration, insufficient osteoinductive potential of these cell-containing TE constructs (TECs) has been implicated. 1, 3 To address this issue, growth factor addition is an appealing strategy.
Bone morphogenetic protein type-2 (BMP-2), belonging to the transforming growth factor (TGF-b) superfamily, is the most extensively studied and potent osteoinductive factor. 2, 3, 5, 10, 16, 17 Recombinant DNA technologies have enabled the production of human BMP-2 and the Food and Drug Administration (FDA) has approved rhBMP-2 commercialization for clinical applications, including delayed-or non-unions. BMP-2 is a pleiotropic cytokine and, among its many roles, it induces osteoblastic differentiation of MSCs and osteoprogenitor cells. [17] [18] [19] However, extremely high doses of BMP-2 (up to 12 mg per application), in contrast to the physiological doses found in a fracture site, are used in clinics for effective bone healing. 5 Adverse side-effects encountered due to these supraphysiologic doses include: Aberrant inflammation, excessive callus, bone resorption, bone voids, and tumor formation. 4, 5, 18, 20 Some studies have shown that combining BMP-2 and MSCs is a relevant strategy. [3] [4] [5] 10, 17, 18, 21, 22 The addition of low-dose BMP-2 to MSC-based TECs for bone regeneration in CSD may indeed sidestep both the low performance of the MSC-containing TECs and the negative effects of supraphysiologic BMP-2 doses.
To the best of our knowledge, this strategy has never been tested in a clinically relevant CSD.
The objective of the present study was to enhance the bone-forming ability of MSC-containing resorbable TECs by the addition of low-dose BMP-2 in a clinically relevant CSD. Our working hypotheses were that (i) the dual delivery of MSCs and BMP-2 would improve bone healing compared with single treatment and (ii) the use of a low-dose of BMP-2 would be sufficient when combined with MSCs. Sheep is an established animal model for bone regenerative preclinical studies as its size, bone metabolism, stem cells, and response to BMP-2 are similar to those of humans.
12,23 Thus, we chose to assess our hypotheses in a CSD (a segmental bone defect twice as long as the diaphyseal diameter) in the metatarsal bone in sheep that (i) mimics the adverse environment encountered in clinical situations; (ii) is well-defined as a CSD (i.e., never heals when left empty); and (iii) exhibits consistent bone healing with autografting procedures. [11] [12] [13] 23 
MATERIALS AND METHODS

Animals
Eighteen healthy, 2-year-old, female Pr e-Alpes sheep, average weight 60 kg, were obtained from a licensed vendor (Institut National de la Recherche Agronomique, Jouyen-Josas, France) and raised in accordance with the European Committee for Care and Use of Laboratory Animals (Dir. 24.11.1986 .86/609/CEE). Animal housing and care were carried out using procedures described in previous publications by members of our team. 12 
Scaffolds
Cube-shaped coral granules with 3 mm edges from the genus Acropora (Biocoral 1 , Inoteb, France) were used as scaffolds.
Coral consists of 99% calcium carbonate in the form of aragonite with 1% organic material. Acropora coral has heterogeneously dispersed and interconnected large pores (412 AE 212 mm), low porosity (12 AE 4%), and high permeability (4.5 Â 10 À9 m 2 ). 11, 24 Cubes were sterilized by autoclaving (at 120˚C for 20 min), which is known to preserve coral composition and structure. 24 Sterile coral cubes were washed with phosphate buffered saline (PBS) before further preparation.
Osteoinductive Factors
Recombinant human BMP-2 (InductOs 1 12 mg, Medtronic, France) solution was reconstituted by dissolving the powder in sterile HCl 1 mM solution (pH ¼ 3) to obtain a concentration of 100 mg/ml (lower concentrations of BMP-2 are known to quickly become instable), aliquoted (2 ml) and kept at À80˚C. The aliquot were thawed and diluted 10 times immediately prior to loading. Dosage was assessed by UV detection at 280 nm (NanoDrop TM 1000 UV-Vis Spectrophotometer, NanoDrop Technologies, Inc.) with the extinction coefficient, based on the peptide sequence, fixed at 1.41 absorbance units per mg/ml.
Autologous Bone Marrow-Derived Mesenchymal Stem Cells (MSCs) MSCs were isolated from bone marrow specimens harvested from the iliac crest of each sheep, 6 weeks prior to implantation. The MSCs were then cultured and amplified in standard culture medium, a-Minimal Essential Medium supplemented with 10% Fetal Bovine Serum (a-MEM þ 10% FBS) as previously described 11 (Supp.1).
Preparation and Characterization Of TECs BMP-Loaded Granules Before coating, sterile granules (n ¼ 60) were washed with 1 mM HCl for 1 h at 4˚C under mild agitation. The granules were then immersed in 7 ml of BMP-2 solution at 10 mg/ml (obtained by dilution of the previous frozen aliquots) under mild shaking at 4˚C for 24 h. The supernatant was removed and kept for BMP-2 assay and granules were washed twice with PBS for 10 min. In order to take into account the amount of BMP-2 adsorbed onto the plasticware, a BMP-2 sham solution was prepared and treated as previously but in the absence of coral (sham sample). The amounts of non-absorbed BMP-2 in both removed supernatants (samples in the presence of coral and sham) were quantified by UV-detection. The amount of protein adsorbed onto the coral granules was calculated as the difference between the initial amount of loaded BMP-2 (corresponding to the BMP-2 non-adsorbed onto plastic determined in the sham solution ) and the BMP-2 non-adsorbed onto both coral and plastic (determined in the sample supernatant in the presence of coral BMP-2 non-adsorbed/coral ). The adsorption rate of BMP-2 onto coral was calculated according to the equation: Adsorption
MSC-Containing Granules
Prior to cell seeding, coral scaffold granules (n ¼ 60) were immersed in culture medium (a-MEM þ 10% FBS) for 24 h. The granules were then loaded with 2 Â 10 5 cells/granule and cultured under sterile static conditions for 1 week at 37˚C. The medium was changed every 3 days. In order to control the distribution and presence of living MSCs on TEC, five granules from each implanted TECs were randomly chosen on the day of surgery and the MSCs covering the granule were either stained with Giemsa (n ¼ 2) or labeled using carboxyfluorescein diacetate succinimidyl ester (CFSE) (n ¼ 3) according to standard techniques. 11 
Bare Scaffold Granules
In order to treat all TECs under the same conditions, granules were either immersed in 1 mM HCl at 4˚C for 24 h followed by twice washing in PBS or in culture medium at 37˚C for 24 h.
All TECs prepared for implantation contained 110 Acropora coral granules by mixing (in a 1:1 ratio) either: (i) BMPgranules:MSC-granules (MSC-BMP-TEC); (ii) BMP-granules: Bare-scaffolds (BMP-TEC); or (iii) MSC-granules:Bare scaffolds (MSC-TEC) ( Table 1 ). The mixing of granules was performed during surgery, immediately before filling the CSD.
Surgical Procedures
Sheep were randomly assigned to three groups according to whether the CSD was filled with either BMP-TECs
general anesthesia, a 25-mm-long mid-diaphyseal metatarsal ostectomy was performed and subsequently stabilized by a plate; the size of the defect corresponded to twofold the mean diameter of the central part of the diaphysis in all sheep (11-12 mm), as previously described (Supp. 2). 23 The resected bone was replaced with one of the TECs, wound closure held it in place. Cranio-caudal radiographs of the operated limb were obtained at the end of surgery and 2 and 4 months postoperatively. The animals were sacrificed after 4 months by barbiturate overdose.
Specimen Collection and Analysis
Immediately after sacrifice, metatarsal bones were excised and fixed in 10% neutral buffered formalin for 2 weeks. The plates were removed and the implant sites, along with 2 cm of the host bone on each end, were resected. These pieces were embedded in methylmethacrylate resin according to established techniques. 12 
Micro-CT Scan Analysis
All embedded specimens were imaged and analyzed with a high-resolution micro-CT (Skyscan1172, Aartselaar, Belgium) with 80 kV source voltage, 100 mA source current, a 26.6 mm pixel size, 180˚rotation, an 1100 ms exposure time, frame averaging 20, and aluminum-copper filters. Samples were reconstructed using NRecon software (Skyscan, Belgium).
Image data sets were first used to produce 3D reconstructions of specimens, using dedicated software (CT Vox v.3.1, Skyscan, Aartselaar, Belgium). Qualitative analysis of bone formation was assessed through examination of the lateral, medial, cranial, and caudal cortices and recording of the number of united cortices for each specimen. Clinical bone healing was defined as union occurring in at least 3/4 cortices.
Quantification of bone volume was performed using available software (CTAn, Skyscan, Aartselaar, Belgium). This software permitted subsequent quantification of (i) the defect volume corresponding to the bone volume of the resected bone and (ii) the newly formed bone and the residual coral on the CSD image data sets. Because bone has a lower degree of mineralization than coral, both bone and coral could be distinguished by their specific thresholds (20-80 and 85-140 gray levels, respectively). Data were analyzed in the same manner for each sheep. The volume of new bone was thus obtained and normalized to the defect volume in each sheep, which assessed the CSD-filling rate (%). The volume of residual coral measured in each defect was normalized to the volume of 110 Acropora cubes measured with the same CT scan parameters. This allowed an estimate of scaffold resorption rate at 4 months postoperatively.
Afterwards, the defect region was divided into three equal parts corresponding to three ROI: (i) the proximal; (ii) the central; and (iii) the distal parts, and the micro-CT analysis described above was performed. The volume of new bone per region was normalized to the total volume of new bone in order to assess the distribution of newly formed bone (%).
Undecalcified Histology
All embedded metatarsal bones were cut longitudinally using a circular saw (200-300 mm, Leitz1600; Leica Inst. Nussloch, Germany). The section closest to the longitudinal midsagittal plane was selected for analysis, ground down to 100 mm thick, polished, and stained with Stevenel blue and van Gieson picrofuchsin.
Statistics
Statistical analyses were performed using a commercially available software package (GraphPad Prism, version 6.0c, GraphPad Software, Inc., La Jolla). According to ShapiroWilk, n was too small for normality testing, thus quantitative data were expressed as median [25th-75th percentile] and data were analyzed using the non-parametric KruskalWallis tests, followed by Dunn's multiple comparison tests. The analysis of contingency by Chi-square test (Yates correction) could not have been performed as less than 20% of the expected values were greater than 5. The significance level was set at a ¼ 0.05.
RESULTS
Preimplantation Characterization BMP-Containing Granules
The adsorption rate of BMP-2 onto coral was 61.8% [58. 3-69.7] . The implanted quantity was 43 mg [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] per sheep.
MSC-Containing Granules
CFSE confirmed that cells were alive at the time of implantation. Giemsa staining showed that the MSC distribution was highly variable, with cells remaining mostly at the periphery of the cubes in all examined TECs (Fig. 1) .
Operative Assessment All animals recovered from surgery and survived until the day of sacrifice. The median volume of the resected bone was 3889 mm 3 , with no difference between groups (p ¼ 0.9). As the implanted amount of BMP-2 was 43 mg on average, the dosage of BMP-2 was estimated at 11 ng/mm 3 of defect.
Bone Formation
Early bone formation in implanted animals was difficult to evaluate with radiographs, because the slow resorption of Acropora scaffold prevented discrimination between the newly formed bone and the remaining scaffold until 4 months. For this reason, bone (Fig. 3) . The differences were not, however, statistically significant (p ¼ 0.6). In addition, the CSD-filling rate tended to be superior in MSC-BMP-TECs (38.7% Interestingly, when comparing the volume of new bone in different parts of the defect, we observed that the bone induced by either BMP-TECs or MSC-TECs in the central part was 2.5-to 3-fold lower than in the proximal part; such a decrease was only of 1.5-fold with MSC-BMP-TECs (Table 2 ) (p ¼ 0.3). Therefore, the new bone distribution was more homogeneous within MSC-BMP-TECs, as the percentage of new bone was statistically similar within the three regions, whereas it was significantly different with other TECs (Fig. 3) (p < 0.0001) .
Histological sections revealed the presence of both mature and immature bone and osteoid, osteocytes, and osteoblasts, both in contact with the remaining coral (even in the core of the cubes) and at a distance from it, similarly in all groups (Fig. 4) . In defects with non-union, fibrous tissue was present and abundant. There was no sign of inflammation or aberrant bone tissue formation in any of the examined slides from explanted specimens.
Scaffold Material Resorption
Results of radiographs obtained 2 months postoperatively were consistent with minimal resorption of the coral granules in most cases. At 4 months, remaining granules were observed on both radiographs and CT-scans in all animals (Fig. 2) , except in the three On the box and whiskers graphs, the box extends from the 25th to the 75th percentile, the line in the middle of the box is plotted at the median, and the whiskers go down to the smallest value and up to the largest. Ã p < 0.0001; ÃÃ p < 0.001; ÃÃÃ p ¼ 0.02. 
DISCUSSION
To the best of our knowledge, this is the first study evaluating the effect of the addition of a low-dose of BMP-2 (11 ng/mm 3 ) to MSC-coral-based TECs for the regeneration of CSD. Our study aimed to address two questions. First, can coral-based TECs combining MSCs and BMP-2 regenerate a clinically relevant CSD more consistently than coral-based TECs loaded with either MSCs or BMP-2? Secondly, can this goal be achieved without the need for supraphysiologic doses of BMP-2? In the present preclinical study, we demonstrated that full bone regeneration of clinically relevant CSD with nearly complete coral resorption could be achieved in 50% of animals using MSC-BMP-TEC. Moreover, the method of preparation we chose, that is, mixing, at the time of surgery, granules selectively preloaded with either BMP-2 or MSCs, can enable future improvements of the TEC through the progressive modification of each individual component to adjust the final osteoinductive/osteogenic potential of the construct.
The use of low-dose BMP-2 is a clinically relevant issue because the lower the quantity required, the lower the cost and, most importantly, the lower the likelihood of adverse side-effects occurring. 4, 5, 18 The choice of the carrier is of paramount importance to avoid the clinical drawbacks emerging when using high doses of BMP-2, as it controls the release of BMP-2 and its local concentration. 5, 25 In the present study, we observed that BMP-2 was highly adsorbed (61.8%) onto coral granules. The low doses of BMP-2 were moreover found to be bioactive, as obtaining bone union (1/5 sheep) in a CSD using BMP-TECs suggested induced bone regeneration. Indeed, the implantation of bare coral scaffolds has been shown to consistently lead to non-union in metatarsal CSD in sheep. 11, 13 These findings provide evidence that coral can provide scaffolding function for BMP-2, but further studies are necessary to explore its potential and relative efficacy compared to other scaffolding systems. Although previous study described coral as a potential carrier for growth factors with sustained in vitro release, 26 the release kinetics of BMP-2 from coral has not been evaluated. Especially as the initial burstrelease of BMP-2 has been shown to be responsible for side-effects. 27 This evaluation is, however, challenging, because both the inflammatory reaction and the degradation of the coral scaffold are supposed to be involved in the release of BMP-2 in vivo. 27 Besides, coral material is well-known to support cell proliferation and differentiation and bone ingrowth. 28 Finally, we observed that the coral granules were highly ($80%) resorbed after 4 months, consistent with results of a previous study demonstrating 99% resorption of Acropora coral scaffold associated with MSCs in sheep 6 months after implantation.
11
This resorbability constitutes an important advantage because complete resorption of the scaffold within 4-6 months postoperatively is recommended in clinical trials for bone regeneration. 24, 29 For all of these reasons, the Acropora coral was chosen as a material scaffold in this study and proved to allow boneingrowth when associated with BMP-2, MSCs, or both, while being resorbed in a timely fashion. However, clinical bone union only occurred in 6/18 CSD. Interestingly, in each group, non-union systematically occurred when coral granules were absent at 4 months postoperatively, suggesting that premature resorption of the coral might be in some cases a reason for failure of healing.
In the present study, clinical healing was achieved in 50% of the CSDs after implantation of coral-based TECs associating low-dose BMP-2 and autologous bone marrow-derived MSCs, without side-effects. Despite no statistical analysis supported it, this healing rate has been reached neither with the other two TECs tested in this study, nor in any other studies evaluating MSC-coral or HA coraline-based TECs in the same model. [11] [12] [13] 30 Plus, the bone formation induced by MSC-BMP-TECs was up to twofold higher than the other TECs, albeit nonsignificant. These results suggested an additive effect of the dual delivery of low-dose BMP-2 and autologous MSCs, which is in accordance with several in vitro and in vivo experimental studies. 17, 18, [31] [32] [33] [34] The bone formation induced by MSC-TECs and BMP-TECs was higher in the proximity of bone ends than in the central region of the defect, indicating that the osteogenic activity in the presence of these TECs was greater at the CSD ends. Indeed, many growth factors and osteoprogenitors are released from the end of a fractured bone. Thus, these data suggest that either the implanted MSCs migrated to the fractured ends under the effect of secreted growth factors or the local osteoprogenitors differentiated there under the osteoinductive effect of the implanted BMP-2. 18 Interestingly, dual delivery of both MSCs and BMP-2 showed an increased bone formation not only at the implant ends, but also at the central region of the defect, where MSC survival was compromised (due to the low vascular supply) and osteoprogenitors were lacking. As a result, it is thought that bone regeneration was reinforced in the central region of the bone defect by the sole osteoinductive property of the MSC-BMP-TEC, which can be explained in several ways.
BMP-2 likely enhances the proliferation and the osteogenic differentiation of MSCs and presumably, their survival, secretory potential, and trophic role. 10, 16, 18, 19, 29, [32] [33] [34] [35] Lastly, the effectiveness of BMP-2 depends on (i) the principle of induction of osteogenesis by resident cells and thus can be improved by increasing cell supply and (ii) the capacity of its carrier to adsorb and deliver appropriate concentrations. 10, 17, 33 Hence, the tripartite combination (MSCs, BMP-2, and coral scaffold) seemed to enhance the biological impact of each component of the TEC.
The degradation of the BMP-TECs was significantly higher than that of MSC-TECs at 4 months postoperatively. BMP-2 could thus have induced coral degradation, which might be considered as an undesirable effect. Actually, it has been proved that BMP-2 enhances osteoclastic activity and coral scaffold resorption is linked to osteoclastic activity. 33 Another possible explanation of different resorption rates between both groups is that, the immunomodulatory and anti-inflammatory properties of MSCs may have limited coral dissolution. 11 Interestingly, the combination of MSCs and BMP-2 led to coral degradation rates between those of TECs loaded with either MSCs or BMP-2. It cannot be emphasized enough how essential it is to control the degradation of the material scaffold for effective bone regeneration. The intermediate degradation profile of MSC-BMP-TECs may be a supplementary reason for their trends toward better bone regeneration. On the one hand, fast resorption of calcium-based scaffold can indeed lead to failure of bone union, 11, 35 as observed in some animals in which complete coral resorption at 4 months was associated with the absence of bone formation. On the other hand, slow resorption can reduce the release of BMP-2 and calcium (key component for mineralization). 5, 11, 35 Despite the improvement of the TEC bone-forming ability, inconsistent union was still observed, as in other studies using MSC-containing TECs. [11] [12] [13] 30 Indeed, a non-union rate of at least 50% is not suitable in clinical practice. A host-related response has been suspected as a potential cause of variations 11, 17, 35 with failure of bone union being a potential consequence of an unsuitable and unpredictable microenvironment. However, previous studies from our group using autograft in the same animal model showed consistent bone healing, 12, 13, 23, 30 indicating that providing that a TEC meets all of the requirements for bone regeneration, the host-related response is not a determinant of success. Many factors can affect the variability of functionality of the TEC, among which is the limited intrinsic osteogenic potential of implanted MSCs (donor and culture condition-dependant). 19 However, variations were still observed with BMP-TECs in absence of MSCs, suggesting that factors related to the scaffold or to BMP-2 contribute to this variation.
The major limitation of our study pertains to the low number of animals implanted and the high interanimal variability; indeed the potential for our study to miss a meaningful effect due to type II error is quite high. Since large animals are costly and cumbersome to monitor, it is not possible to conduct large, wellpowered studies to examine each variable in the same way as is usual with rodents. 22 Another limitation was the unbalanced design of the study, which was due to (i) ethical issues concerning the use of the minimal number of animal (3R principles) and (ii) the different inter-animal variations expected in results with the different TECs. Indeed, using MSC-TECs, [11] [12] [13] 30 results are reported to be associated with great variations, which was confirmed in our study (coefficient of variation 74%, n ¼ 7). It is indeed well known that cells of autologous origin have different potentials LOW-DOSE BMP-2-MSC-CORAL-CONSTRUCTS FOR BONE REGENERATION in vitro. We had hypothesized that variations in results would not be as important using a commercialized drug. Unfortunately, in our study, the BMP-TEC group (n ¼ 5) showed also great variations, which was not expected (75%).
Another limitation is the choice of what we defined as low-dose BMP-2. Although it has been demonstrated that BMP-2 stimulates bone formation in a dose-dependent manner, 31, 33 the optimal dose of BMP-2 to induce bone formation without generating adverse effects (which depends on several factors such as species) remains undetermined. 36 In previous studies in sheep, BMP-2 was applied at doses of 150-200 ng/mm 3 with demineralized bone matrix or inactive bone matrix scaffolds in a critical-sized diaphyseal femoral defect 37, 38 and at a dose of 200 ng/mm 3 on tricalcium phosphate scaffold in an epiphyseal femoral defect. 39 On the basis of these values, and being aware of the fact that the use of a different carrier may impact the adsorption and delivery of BMP-2, a dose of 11 ng/mm 3 was chosen in the present study, corresponding to an approximately 20-fold decrease relative to doses currently used in sheep and at least a 130-fold decrease relative to the one used in clinical situations (1500 ng/mm 3 ). 10 This dose is, to the best of our knowledge, the lowest one ever reported in a large animal CSD model. Increasing the BMP-2 doses to further improve the performance of MSCs-coral based TECs without generating any side-effects remains an open question. 4 This would require further in vitro study to evaluate the release kinetic profile of such a TEC, especially the initial burst-release of BMP-2 that might be higher using increased initial dosages and might increase the risk of side-effects. This evaluation is, however, challenging, because both the inflammatory reaction and the degradation of the coral scaffold are supposed to be involved in the release of BMP-2 in vivo. 27 Nevertheless, some authors showed that the use of higher doses of BMP-2 could rule out any advantage from its combination with MSCs and that there is a limit dose above which bone formation is not increased.
39,40
CONCLUSIONS
Our study provided evidence that, combined with coral scaffolds, the dual delivery of low-dose BMP-2 and autologous bone-marrow derived-MSCs tended to improve bone formation compared with that mediated by single treatment of either MSC or BMP-2. However, in 50% of the CSB, healing was not achieved, suggesting that either the dose of BMP-2 might be too low or that other factors are needed. These results, above all, suggested that an insufficient osteoinductive potential in TECs contributes to the inconsistency of healing induced by MSC-based therapies and open up new avenues for the development of safer and more predictable tissue-engineering strategies. 
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